We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Skip to main content

Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate

Summary

The absorption, distribution, and elimination kinetics of low-dose p.o. methotrexate (MTX) were repeatedly studied in 19 children during maintenance treatment of childhood acute lymphoblastic leukemia. Plasma concentrations, urinary elimination, and bone marrow concentrations of MTX and 7-hydroxymethotrexate (7-OH-MTX) were monitored during 24 h following a routime p.o. dose (30 mg/m2) using high-pressure liquid chromatography. Significant interindividual variability was found in time to peak concentration (30–180 min), peak concentration (0.41–2.77 μM), and to a lesser extent the half-lives (t1/2α: 32.8–86.1 min; t1/2β: 43.6–350.0 min; t1/2 absorption: 25.2–60.3 min) and plasma area under the concentration-time curve from zero to infinity (195.6–818.5 μM.min). Significant amounts of 7-OH-MTX were detected in plasma, with a mean area under the concentration-time curve from zero to infinity of 208 μM.min compared with 365.6 μM.min for MTX. High concentrations of 7-OH-MTX were present in bone marrow 24 h after oral MTX (15/19 patients) and were at least five fold those in plasma and three fold the concentration of MTX in bone marrow. In four patients occasionally neither MTX nor metabolite could be detected. Repeated examination of these pharmacokinetic parameters in plasma and bone marrow showed that the intraindividual variability was small.

This is a preview of subscription content, access via your institution.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

References

  1. Aherne GW, Quinton M (1981) Techniques for the measurement of methotrexate in biological samples. Cancer Treat Rep [Suppl 1] 65: 55

    Google Scholar 

  2. Balis FM, Savitch JL, Bleyer WA (1983) Pharmacokinetics of oral methotrexate in children. Cancer Res 43: 2342

    Google Scholar 

  3. Canfell C, Sadée W (1980) Methotrexate and 7-hydroxymethotrexate: serum level monitoring by high performance liquid chromatography. Cancer Treat Rep 64: 165

    Google Scholar 

  4. Chan KK, Balachandran Nayar MS, Cohen JL, Chlebowsky RT, Liebman H, Stolinsky D, Farquhar D (1980) Metabolism of methotrexate in man after high and conventional doses. Res Commun Chem Pathol Pharmacol 28: 551

    Google Scholar 

  5. Craft AW, Rankin A, Aherne W (1981) Methotrexate absorption in children with acute lymphoblastic leukaemia. Cancer Treat Rep [Suppl 1] 65: 77

    Google Scholar 

  6. Erttman R, Bielack S, Landbeck G (1985) Kinetics of 7-hydroxymethotrexate after high dose methotrexate therapy. Cancer Chemother Pharmacol 15: 101

    Google Scholar 

  7. Evans WE, Hutson PR, Stewart CF (1983) Methotrexate cerebrospinal fluid and serum concentrations after intermediatedose methotrexate infusions. Clin Pharmacol Ther 33: 301

    Google Scholar 

  8. Evans WE, Stewart CF, Chen CH, Cran WR, Bowman WP, Abromowitch M, Simone JV (1984) Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet 1: 359

    Google Scholar 

  9. Fabre G, Matherly LH, Fabre I, Cano JP, Goldman ID (1984) Interactions between 7-hydroxymethotrexate and methotrexate at the cellular level in the Ehrlich Ascites tumor in vitro. Cancer Res 44: 970

    Google Scholar 

  10. Farquhar D, Loo TL, Vadlamudi S (1972) Synthesis and biological evaluation of 7-hydroxymethotrexate, 7-methylaminopterin and 7-methylmethotrexate. J Med Chem 15: 567

    Google Scholar 

  11. Howell SK, Wang YM, Hosoya R, Sutow WW (1980) Plasma methotrexate as determined by liquid chromatography, enzyme-inhibition assay and radio-immunoassay after high dose infusion. Clin Chem 26: 734

    Google Scholar 

  12. Jacobs SA, Stoller RG, Chabner BA, Johns DG (1976) 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high-dose methotrexate. J Clin Invest 57: 534

    Google Scholar 

  13. Jacobs SA, Stoller RG, Chabner BA, Johns DG (1977) Dosedependent metabolism of methotrexate in man and rhesus monkeys. Cancer Treat Rep 61: 651

    Google Scholar 

  14. Kamen BA, Holcenberg JS, Turo K, Whitehead VM (1983) Variability of red blood cell folate and methotrexate in children with acute lymphocytic leukemia. Proc. Am Assoc Cancer Res 135 (abstract)

  15. Kearney PJ, Light PA, Preece A, Mott MG (1979) Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 3: 117

    Google Scholar 

  16. Lankelma J, Poppe H (1978) Determination of methotrexate in plasma by on-column concentration and ion-exchange chromatography. J Chromatogr 149: 587

    Google Scholar 

  17. Lankelma J, van der Klein E (1980) The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. Cancer Lett 9: 133

    Google Scholar 

  18. Pearson ADJ, Craft AW, Eastham EJ, Aherne GW, Littleton P, Pearson GL, Campbell AN (1985) Small intestinal transit time affects methotrexate absorption in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 14: 211

    Google Scholar 

  19. Pinkerton CR, Welshman SG, Dempsey SI, Bridges JM, Glasgow JFT (1980) Absorption of methotrexate under standardised conditions in children with acute lymphoblastic leukaemia. Br J Cancer 42: 613

    Google Scholar 

  20. Pinkerton CR, Glasgow JFT, Bridges JM, Welshman SG (1981) Enterotoxic effect of methotrexate: does it influence the drug's absorption in children with acute lymphoblastic leukaemia? Br Med J 282: 1276

    Google Scholar 

  21. Piper JR, McCaleb GS, Montgomery JA, Kisliuk RL, Gaumant Y, Sirotnah FM (1982) 10-Propargylaminopterin and alkyl homologues of methotrexate as inhibitors of folate metabolism. J Med Chem 25: 877

    Google Scholar 

  22. Stam AJ, Van der Kogel AJ, Nooter K (1985) Effect of X-irradiation on the pharmacokinetics of methotrexate in rats: alteration of the blood-brain barrier. Eur J Cancer Clin Oncol 21: 759

    Google Scholar 

  23. Stewart AL, Margison JM, Wilkinson PM, Lucas SB (1985) The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy. Cancer Chemother Pharmacol 14: 165

    Google Scholar 

  24. Wagner J (1975) Fundamentals of clinical pharmacokinetics. Hamilton, Ill.

  25. Wang YM, Howell SK, Smith RG, Hosoya K, Benvenuto JA (1979) Effect of metabolism on pharmacokinetics and toxicity of high-dose methotrexate therapy in children. Proc Am Soc Clin Oncol 20: 334

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

This study was supported by the Netherlands Cancer Foundation “Koningin Wilhelmina Fonds”

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sonneveld, P., Schultz, F.W., Nooter, K. et al. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. Cancer Chemother. Pharmacol. 18, 111–116 (1986). https://doi.org/10.1007/BF00262278

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00262278

Keywords

  • Bone Marrow
  • Leukemia
  • Methotrexate
  • Peak Concentration
  • Acute Lymphoblastic Leukemia